Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus placebo for idiopathic membranous nephropathy with nephrotic syndrome
jRCT2041230037Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of rituximab in idiopathic membranous glomerulonephritis (IMG) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Percentage of patients achieving ICR I. Started Jun 2023; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on jRCT2041230037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230037.